Absci NasdaqGS:ABSI Stock Report Company Financials + 8 Analysts
Absci Corporation
NasdaqGS:ABSI Stock Report
ABSI Stock Overview Operates as a data-first generative artificial intelligence (AI) drug creation company in the United States.
Rewards Risk Analysis See All Risk Checks Absci Corporation Competitors Price History & Performance
Summary of all time highs, changes and price drops for Absci Historical stock prices Current Share Price US$3.14 52 Week High US$6.72 52 Week Low US$1.29 Beta 2.19 11 Month Change -23.41% 3 Month Change -24.15% 1 Year Change 124.29% 33 Year Change -74.55% 5 Year Change n/a Change since IPO -85.46%
Recent News & Updates See more updates
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Nov 13
Is Absci (NASDAQ:ABSI) A Risky Investment? Nov 13
Absci: Embryonic Pipeline Looks Expensive Relative To Peers Oct 29
Absci Corporation to Report Q3, 2024 Results on Nov 12, 2024 Oct 15
Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile Oct 03
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 15
Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships Jul 28
Absci Corporation to Report Q2, 2024 Results on Aug 14, 2024 Jul 11
Is Absci (NASDAQ:ABSI) A Risky Investment? Jun 17
Chief Business Officer & CFO notifies of intention to sell stock Jun 16
Chief Business Officer & CFO notifies of intention to sell stock Jun 16
Consensus revenue estimates decrease by 26% May 21
Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula May 16
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 16 Absci Corporation to Report Q1, 2024 Results on May 14, 2024 Apr 17
Consensus revenue estimates fall by 20% Mar 28
Full year 2023 earnings: EPS in line with expectations, revenues disappoint Mar 21
Consensus revenue estimates decrease by 13% Mar 06
New minor risk - Shareholder dilution Feb 29
Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million. Feb 29 Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.
Absci: Differentiated Antibody Discovery Play Feb 27
Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai Feb 23
Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference Jan 08
Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024 Dec 08
Price target decreased by 14% to US$5.76 Dec 05
Consensus revenue estimates decrease by 42% Nov 24
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 17
Price target decreased by 15% to US$5.50 Oct 10
Consensus EPS estimates fall by 21%, revenue upgraded Aug 21
Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023 Aug 18 Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023
Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023 Aug 15
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 14
Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development Aug 11
New major risk - Share price stability Jul 06
Absci Corporation Appoints Frans Van Houten to Its Board of Directors Jun 08
Price target decreased by 10% to US$7.73 Jun 04
First quarter 2023 earnings: EPS and revenues miss analyst expectations May 17
Casdin Capital Engages in Discussions with Absci Corporation May 10
Price target decreased by 28% to US$8.60 Apr 13
Consensus revenue estimates decrease by 23%, EPS upgraded Apr 06
Full year 2022 earnings: EPS in line with expectations, revenues disappoint Mar 31
Casdin Capital Engages in Discussions with Absci Corporation Feb 14
Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation Feb 09
Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI Jan 11
Consensus forecasts updated Nov 18
Price target decreased to US$12.10 Nov 16
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors Nov 03
Chief Financial Officer exercised options to buy US$155k worth of stock. Oct 25
Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer Oct 06
Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer Sep 21
Price target decreased to US$13.10 Aug 24
Second quarter 2022 earnings: EPS and revenues miss analyst expectations Aug 12
Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M Aug 11 Eli Casdin Resigns from Board of Directors of Absci Corporation
Absci teams up to help develop antibody drugs for cancer Jul 07 Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index
First quarter 2022 earnings: EPS and revenues miss analyst expectations May 13
High number of new and inexperienced directors Apr 27
Consensus EPS estimates fall by 29% Mar 29
Consensus revenue estimates fall by 17% Mar 09
Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out Jan 10
High number of new and inexperienced directors Dec 31
Third quarter 2021 earnings released: US$0.33 loss per share Nov 10
Absci, CORP has completed an IPO in the amount of $200 million. Jul 23
IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video) Jul 22 Shareholder Returns ABSI US Biotechs US Market 7D -24.2% -1.3% 3.9% 1Y 124.3% 22.8% 33.2%
See full shareholder returns
Return vs Market: ABSI exceeded the US Market which returned 33.2% over the past year.
Price Volatility Is ABSI's price volatile compared to industry and market? ABSI volatility ABSI Average Weekly Movement 10.2% Biotechs Industry Average Movement 9.7% Market Average Movement 6.2% 10% most volatile stocks in US Market 15.4% 10% least volatile stocks in US Market 3.0%
Stable Share Price: ABSI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ABSI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.
Show more Absci Corporation Fundamentals Summary How do Absci's earnings and revenue compare to its market cap? ABSI fundamental statistics Market cap US$418.07m Earnings (TTM ) -US$97.67m Revenue (TTM ) US$4.21m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ABSI income statement (TTM ) Revenue US$4.21m Cost of Revenue US$47.57m Gross Profit -US$43.36m Other Expenses US$54.31m Earnings -US$97.67m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.85 Gross Margin -1,030.66% Net Profit Margin -2,321.56% Debt/Equity Ratio 2.7%
How did ABSI perform over the long term?
See historical performance and comparison
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
